These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8497414)

  • 21. Thalidomide: new preparation. For well-defined indications.
    Prescrire Int; 1998 Oct; 7(37):131-4. PubMed ID: 10848043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic graft-versus-host disease: a prospective cohort study.
    Arora M; Burns LJ; Davies SM; Macmillan ML; Defor TE; Miller WJ; Weisdorf DJ
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):38-45. PubMed ID: 12533740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thalidomide and graft verses host disease: basis for a new indication and side effects].
    López Gil JA
    Med Clin (Barc); 1992 Oct; 99(14):545-8. PubMed ID: 1434991
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of thalidomide in chronic refractory graft versus host disease.
    van de Poel MH; Pasman PC; Schouten HC
    Neth J Med; 2001 Aug; 59(2):45-9. PubMed ID: 11476911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide for graft-versus-host disease after bone marrow transplantation.
    Saurat JH; Camenzind M; Helg C; Chapuis B
    Lancet; 1988 Feb; 1(8581):359. PubMed ID: 2893167
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation.
    Lim SH; McWhannell A; Vora AJ; Boughton BJ
    Lancet; 1988 Jan; 1(8577):117. PubMed ID: 2891954
    [No Abstract]   [Full Text] [Related]  

  • 28. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Martin SJ; Audrain MA; Oksman F; Ecoiffier M; Attal M; Milpied N; Esnault VL
    Bone Marrow Transplant; 1997 Jul; 20(1):45-8. PubMed ID: 9232255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalidomide for chronic GVHD.
    Sastry PS; Powles RL
    Bone Marrow Transplant; 1998 Nov; 22(9):933-4. PubMed ID: 9827827
    [No Abstract]   [Full Text] [Related]  

  • 31. Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study.
    Nagler RM; Nagler A
    Bone Marrow Transplant; 1999 May; 23(10):1007-11. PubMed ID: 10373066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation.
    Saad AG; Alyea EP; Wen PY; Degirolami U; Kesari S
    J Clin Oncol; 2009 Oct; 27(30):e147-9. PubMed ID: 19667266
    [No Abstract]   [Full Text] [Related]  

  • 33. Thalidomide for graft-versus-host disease.
    McCarthy DM; Kanfer E; Taylor J; Barrett AJ
    Lancet; 1988 Nov; 2(8620):1135. PubMed ID: 2903342
    [No Abstract]   [Full Text] [Related]  

  • 34. Phases in a drug's use.
    Duffin J
    CMAJ; 1992 Sep; 147(5):588. PubMed ID: 1521204
    [No Abstract]   [Full Text] [Related]  

  • 35. Cytomegalovirus infections in transplant patients.
    Ljungman P
    Scand J Infect Dis Suppl; 1996; 100():59-63. PubMed ID: 8860355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
    Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
    Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide for severe acute graft-versus-host disease.
    Ringdén O; Aschan J; Westerberg L
    Lancet; 1988 Sep; 2(8610):568. PubMed ID: 2900947
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report.
    Hayashi T; Morishita E; Ontachi Y; Yamazaki M; Asakura H; Yoshida T; Nakao S
    Am J Hematol; 2006 Feb; 81(2):121-3. PubMed ID: 16432874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry.
    del Cañizo MC; Martínez C; Conde E; Vallejo C; Brunet S; Sanz G; Mateos MV;
    Bone Marrow Transplant; 2003 Nov; 32(10):987-92. PubMed ID: 14595386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment with thalidomide and production of tumor necrosis factor alpha].
    Pizarro A; Pinilla J; García-Tobaruela A
    Med Clin (Barc); 1993 Jun; 101(4):158. PubMed ID: 8355553
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.